Contingent Consideration - Narrative (Details) $ / shares in Units, $ in Thousands			3 Months Ended			9 Months Ended
	Jul. 31, 2025 USD ($) right $ / shares	Nov. 24, 2021 USD ($) right $ / shares	Sep. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Jun. 16, 2025 $ / shares	Dec. 31, 2024 USD ($) milestone
Business Combination [Line Items]
Fair value gain (loss) recognized in earnings						$ (7,660)	$ 6,466
Payment of contingent consideration						24,257	0
Contingent consideration			$ 11,448			11,448			$ 47,340
Change in fair value of contingent consideration			0		$ (1,016)	7,660	(6,466)
USWM Acquisition
Business Combination [Line Items]
Number of outstanding milestones | milestone									2
Fair value gain (loss) recognized in earnings			0		(1,300)	(7,660)	(130)
Contingent consideration, maximum			25,000			25,000
USWM Acquisition | ONAPGO
Business Combination [Line Items]
Number of outstanding milestones | milestone									1
USWM Acquisition | Subsequent Commercial Product Launch
Business Combination [Line Items]
Contingent consideration, maximum			30,000			30,000
Payment of contingent consideration			1,900	$ 2,300
Contingent consideration			25,800			25,800
Adamas Acquisition
Business Combination [Line Items]
Fair value gain (loss) recognized in earnings					$ 2,300	0	$ 6,596
Contingent consideration, maximum			25,000			25,000
Contingent consideration			0			0			$ 0
Contingents value rights | right		2
Contingent consideration arrangements, value (in dollars per share) | $ / shares		$ 0.50
Contingent consideration, minimum			0			0
Adamas Acquisition | The Milestones
Business Combination [Line Items]
Contingent consideration arrangements, excess acquisition date fair value		$ 225,000
Contingent consideration arrangements, excess acquisition date fair value, term		12 months
Sage Therapeutics, Inc.
Business Combination [Line Items]
Fair value gain (loss) recognized in earnings						0
Contingent consideration, maximum	$ 234,000
Contingent consideration	$ 11,448
Contingents value rights | right	1
Contingent consideration, minimum	$ 0
Rights per share (in dollars per share) | $ / shares	$ 3.50							$ 3.50
Change in fair value of contingent consideration			$ 0			$ 0
Sage Therapeutics, Inc. | CVR Agreement
Business Combination [Line Items]
Rights per share (in dollars per share) | $ / shares	3.50
Sage Therapeutics, Inc. | Annual Net Sales of ZURZUVAE 2027 | CVR Agreement
Business Combination [Line Items]
Rights per share (in dollars per share) | $ / shares	$ 1.00
Business combination, contingent consideration, threshold, annual net sales	$ 250,000
Sage Therapeutics, Inc. | Annual Net Sales of ZURZUVAE 2028 | CVR Agreement
Business Combination [Line Items]
Rights per share (in dollars per share) | $ / shares	$ 1.00
Business combination, contingent consideration, threshold, annual net sales	$ 300,000
Sage Therapeutics, Inc. | Annual Net Sales of ZURZUVAE 2030 | CVR Agreement
Business Combination [Line Items]
Rights per share (in dollars per share) | $ / shares	$ 1.00
Business combination, contingent consideration, threshold, annual net sales	$ 375,000
Sage Therapeutics, Inc. | First Commercial Sale In Japan For ZURZUVAE | CVR Agreement
Business Combination [Line Items]
Rights per share (in dollars per share) | $ / shares	$ 0.50